IL23A (Risankizumab biosimilar) Antibody from ABBEXA LTD
Search, find, compare suppliers for anti-IL23A (Risankizumab biosimilar) antibody, protein, ELISA kits.
| Edit | |
|---|---|
| Antigenic Specificity | IL23A (Risankizumab biosimilar) |
| Clone | monoclonal |
| Host Species | Recombinant Human |
| Reactive Species | human |
| Isotype | IgG1 kappa |
| Format | Protein A/G purified |
| Size | 100 µg, 1 mg, |
| Concentration | typically between 0.5-2.0 mg/ml. |
| Applications | ELISA, WB |
| Reviews / Ratings | If you have used this antibody, please help fellow researchers by submitting reviews to pAbmAbs and antYbuddY. |
| Description | Risankizumab is a monoclonal antibody biosimilar expressed in CHO cells, targeting IL23A, for use in laboratory research applications. This product is not suitable for use as medicines or in human, therapeutic or diagnostic applications. Risankizumab is a fully humanized IgG1 monoclonal antibody (mAb) that is selective for interleukin 23 (IL-23). On April 23, 2019 it was approved by the FDA (as SKYRIZI) for the treatment of moderate-to-severe plaque psoriasis in adults who are clinically considered eligible for systemic therapy or phototherapy for psoriasis. Label This drug has been commercialized through collaboration between the German pharmaceutical company, Boehringer Ingelheim, and Abbvie. |
| Immunogen | n/a |
| Other Names | Risankizumab, IL23A, 1612838-76-2 |
| Gene, Accession # | CAS: 1612838-76-2 |
| Catalog # | abx831355 |
| Price | please inquire |
| Order / More Info | IL23A (Risankizumab biosimilar) Antibody from ABBEXA LTD |
| Product Specific References | n/a |
ABBEXA LTD
ABBEXA LTD
181 Cambridge Science Park
Cambridge, CB4 0GJ UK
P: +44 (0) 1223 755950
Customer Service: info@abbexa.com
Technical Support: support@abbexa.com
Orders: orders@abbexa.com
https://www.abbexa.com
U.S. Office
118 Eldridge Rd, Suite C,
Sugar Land, TX 77478 USA
Telephone: +1 832 327 7413
Netherlands Office
Abbexa BV
Wattstraat 54 2723 RD,
Zoetermeer,Netherlands
Telephone: +44 (0) 1223 755950
Profile of ABBEXA LTD
Return to Antibodies